USA - NASDAQ:THRD - US88427A1079 - Common Stock
ChartMill assigns a Buy % Consensus number of 43% to THRD. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-28 | Stifel | Downgrade | Buy -> Hold |
| 2025-02-12 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-02-11 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2024-08-09 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2024-06-18 | Stifel | Initiate | Buy |
| 2024-06-07 | Raymond James | Initiate | Outperform |
| 2023-08-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2022-12-16 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-12-16 | Jefferies | Downgrade | Buy -> Hold |
| 2022-10-10 | Cowen & Co. | Initiate | Outperform |
| 2022-10-10 | Morgan Stanley | Initiate | Overweight |
| 2022-10-10 | Jefferies | Initiate | Buy |
6 analysts have analysed THRD and the average price target is 3.06 USD. This implies a price decrease of -43.12% is expected in the next year compared to the current price of 5.38.
The consensus rating for Third Harmonic Bio Inc (THRD) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering Third Harmonic Bio Inc (THRD) is 6.